



**PRIOR AUTHORIZATION REQUEST FORM  
DOJOLVI™**

**For authorization, please answer each question and fax this form PLUS chart notes back to Real Rx at 385-425-4052.**

**Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

If you have prior authorization questions, please call for assistance 385-425-5094.

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

|               |              |                 |
|---------------|--------------|-----------------|
| Date:         | Member Name: | ID#:            |
| DOB:          | Gender:      | Physician:      |
| Office Phone: | Office Fax:  | Office Contact: |

Height/Weight:

**Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.**

**Product being requested:**  Dojolvi™ (triheptanoin)

Dosing/Frequency: \_\_\_\_\_

**If the request is for reauthorization, proceed to reauthorization section.**

| Questions  | Yes                      | No                       | Comments/Notes                      |
|--|--------------------------|--------------------------|-------------------------------------|
| 1. Is this request for an <b>expedited</b> review?<br>By checking the “ <b>Yes</b> ” box to request an expedited review (24 hours), you are certifying that applying the standard review time frame (72 hours) may place the member's life, health, or ability to regain maximum function in serious jeopardy.   | <input type="checkbox"/> | <input type="checkbox"/> |                                     |
| 2. Is the therapy prescribed by, or in consultation with, a metabolic disease specialist or a physician who specializes in the management of long-chain fatty acid oxidation disorders?  | <input type="checkbox"/> | <input type="checkbox"/> |                                     |
| 3. Does the member have a molecularly confirmed diagnosis of a long-chain fatty acid oxidation disorder based on 2 of the following: <ul style="list-style-type: none"> <li>• Disease-specific acylcarnitine elevations on a newborn blood spot or in plasma</li> <li>• Enzyme activity assay (in cultured fibroblasts or lymphocytes) below the lower limit of normal</li> <li>• Genetic testing demonstrating pathogenic mutations in a gene associated long-chain fatty acid oxidation disorders</li> </ul> | <input type="checkbox"/> | <input type="checkbox"/> | <b>Please provide documentation</b> |
| 4. Is the member receiving disease related dietary management?   | <input type="checkbox"/> | <input type="checkbox"/> | <b>Please provide documentation</b> |

**REAUTHORIZATION**

|   |                          |                          |                                     |
|---|--------------------------|--------------------------|-------------------------------------|
| 1. Is the request for reauthorization of therapy?                                       | <input type="checkbox"/> | <input type="checkbox"/> |                                     |
| 2. Does updated clinical documentation show disease progression or toxicity to therapy? | <input type="checkbox"/> | <input type="checkbox"/> | <b>Please provide documentation</b> |

**What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.**

Additional information:

Physician Signature:

**\*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\***

Policy: PHARM-112  
Origination Date: 12/10/2020  
Reviewed/Revised Date: 01/18/2023  
Next Review Date: 01/18/2024  
Current Effective Date: 02/01/2023

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.